Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | MMP17 | Q9ULZ9 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880883 | 0.93 | MMP13 (0.47) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3881640 | 0.88 | ADAM17 (0.43) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3880925 | 0.85 | ADAM17 (0.54) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3880990 | 0.85 | MMP2 (0.63) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3881178 | 0.84 | MMP13 (0.47) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3883072 | 0.82 | FFAR1 (0.47) | FFAR1SPHK1SPHK2PARP10 | |
| SCHEMBL3887844 | 0.81 | ADAM17 (0.46) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3884156 | 0.78 | MMP2 (0.68) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3887431 | 0.78 | FFAR1 (0.36) | MMP2MMP3MMP13ADAM17MMP17 | |
| SCHEMBL3887435 | 0.78 | FFAR1 (0.36) | MMP2MMP3MMP13ADAM17MMP17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | MMP2 58/4885MMP3 55/4885MMP13 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.